295 related articles for article (PubMed ID: 33001386)
1. A Narrative Review of the Role of Transthyretin in Health and Disease.
Liz MA; Coelho T; Bellotti V; Fernandez-Arias MI; Mallaina P; Obici L
Neurol Ther; 2020 Dec; 9(2):395-402. PubMed ID: 33001386
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Ruberg FL; Maurer MS
JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
[TBL] [Abstract][Full Text] [Related]
3. The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism.
Sanguinetti C; Minniti M; Susini V; Caponi L; Panichella G; Castiglione V; Aimo A; Emdin M; Vergaro G; Franzini M
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009453
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
5. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis.
Raghu P; Sivakumar B
Biochim Biophys Acta; 2004 Dec; 1703(1):1-9. PubMed ID: 15588697
[TBL] [Abstract][Full Text] [Related]
6. Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy.
Ioannou A; Fontana M; Gillmore JD
Heart Int; 2023; 17(1):27-35. PubMed ID: 37456349
[TBL] [Abstract][Full Text] [Related]
7. Transthyretin Stabilization: An Emerging Strategy for the Treatment of Alzheimer's Disease?
Saponaro F; Kim JH; Chiellini G
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212973
[TBL] [Abstract][Full Text] [Related]
8. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9629-34. PubMed ID: 22645360
[TBL] [Abstract][Full Text] [Related]
9. Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis.
Matsushita H; Misumi Y; Masuda T; Okada M; Inoue F; Ueda M; Ando Y
Pathophysiology; 2022 Jun; 29(3):333-343. PubMed ID: 35893595
[TBL] [Abstract][Full Text] [Related]
10. Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities.
Cioffi CL; Raja A; Muthuraman P; Jayaraman A; Jayakumar S; Varadi A; Racz B; Petrukhin K
J Med Chem; 2021 Jul; 64(13):9010-9041. PubMed ID: 34138572
[TBL] [Abstract][Full Text] [Related]
11. Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights.
Koike H; Katsuno M
Biomedicines; 2019 Feb; 7(1):. PubMed ID: 30764529
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.
Coelho T; Merlini G; Bulawa CE; Fleming JA; Judge DP; Kelly JW; Maurer MS; Planté-Bordeneuve V; Labaudinière R; Mundayat R; Riley S; Lombardo I; Huertas P
Neurol Ther; 2016 Jun; 5(1):1-25. PubMed ID: 26894299
[TBL] [Abstract][Full Text] [Related]
13. Transthyretin: roles in the nervous system beyond thyroxine and retinol transport.
Oliveira SM; Cardoso I; Saraiva MJ
Expert Rev Endocrinol Metab; 2012 Mar; 7(2):181-189. PubMed ID: 30764010
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
15. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.
Si JB; Kim B; Kim JH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922648
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases.
Park GY; Jamerlan A; Shim KH; An SSA
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31216785
[TBL] [Abstract][Full Text] [Related]
17. Transthyretin: Its function and amyloid formation.
Ueda M
Neurochem Int; 2022 May; 155():105313. PubMed ID: 35218869
[TBL] [Abstract][Full Text] [Related]
18. Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy.
Falcão de Campos C; Conceição I
Drug Healthc Patient Saf; 2023; 15():51-62. PubMed ID: 36824481
[TBL] [Abstract][Full Text] [Related]
19. Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy.
Kotit S
Glob Cardiol Sci Pract; 2023 Jan; 2023(1):e202304. PubMed ID: 37928601
[No Abstract] [Full Text] [Related]
20. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
